Endogenous ethanol and microbe associations at patients with alcoholic dependence

N. Perminova, M. Chuhrova, I. Timofeyev. State Research Center of Virology & Biotechnology "Vector", Institute of Internal Therapy, SB RAMS, Russia

Systematic usage of alcohol results in predominance of lipid metabolism in comparison with carbohydrate metabolism. Synthesis of endogenous ethanol is decreased. This is the only cause of decreasing of endogenous ethanol synthesis. We found that patients suffering from alcoholism have essentially disturbed microbe ensemble in bowels. This dysbacteriosis not only disturbs their immune reactivity, results in deficiency in vitamins, aminocids and other biologically active compounds, but also deprives organism of endogenous ethanol synthesized by some symbiotic microorganisms. Alcoholic dysbacteriosis indirectly causes appearance of fermentative pathology – decreasing of cycle Krebs enzymes activity that aggravates suppression of carbohydrate metabolism. Treatment of patients suffering from alcoholic dependence with probiotics such as bifidumbacterine and lactobacterine is insufficiently effective. We obtained combined bacterial preparation containing immobilized on the activated charcoal microbe association. These microorganisms consecutively enter into vital functions resulting in marked positive changes. Patients noted decreasing of need for alcohol. The level of endogenous ethanol in the blood increased, content of glucose and lipids, activities of lactate dehydrogenase, pyruvate kinase, aldehyde dehydrogenase, oxydoreductases normalized, activity of transferases decreased.

Efficacy of oxcarbazepine in alcohol relapse prevention – a pilot study

B. Croissant, T. Scherle, A. Heinz, K. Mann. University of Heidelberg, Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Mannheim, Germany

Introduction: The anticonvulsant carbamazepine is used in alcohol withdrawal. It also reduced the relapse risk in a double-blind pilot study with 29 patients (Autor et al 1992). However, its use in alcoholics is often limited because of its metabolism in the liver and hepatic impairment in alcoholism. This problem could be addressed by the use of the carbamazepine-derivative oxcarbazepine, because unlike carbamazepine it is only metabolized by specific isoenzymes of the cytochrome P-450 3A group. No epoxide emerges in the metabolism, which explains the better tolerability of oxcarbazepine.

Methods: We evaluated oxcarbazepine for relapse prevention in ten high risk patients, who had repeatedly (mean 5 times in about 10 years of dependence) relapsed after detoxification and who had also failed to respond to acamprosate. Patients were seen weekly in our outpatient clinic after detoxification and received about 900mg oxcarbazepine per day. All Patients fulfilled ICD-10 criteria for alcoholism and suffered from other psychiatric disorder.

Results: Ten patients were treated, the overall tolerability was good. Four patients remained abstinent for at least 15 weeks (mean 20 weeks) under treatment, while treatment had to be terminated in four patients due to side effects, mainly an allergic skin reaction in three patients. Two more patients relapsed under oxcarbazepin medication.

Conclusion: Altogether, oxcarbazepin might warrant further investigation and may be useful in preventing alcohol relapse in some previously treatment-resistant alcoholics.
Methods: Ten multidrug detoxification inpatients treated with a topiramate-protocol were compared to 10 patients treated with a clonidine-scheme and 10 patients treated with a carbamazepine-mianserine protocol. Comedication, protocol deviations (dose augmentation or reduction) and retention in treatment were compared between groups.

Results: There were significantly less protocol deviations in the topiramate group compared to the other two groups. Topiramate treated patients were less often given anxiomtics and sedative antipsychotic drugs. The retention in treatment was comparable between the 3 groups.

Conclusions: Topiramate is a well tolerated and seemingly efficient alternative to standard withdrawal treatments for multidrug users.

P55.04
Longitudinal study of psychiatric comorbidity in MDMA users
J.M. Gines, R. Blanco, M. Torrens, R. Martin-Santos, S. Pouveida, P.N. Roset, M. Farre, R. de la Torre. Instituto Municipal de Investigacion Medica (IMIM), Grupo de Recerca en Psiquiatria, Unitat de Recerca en Farmacologia, Spain

Introduction: Prevalence and relationship between psychiatric comorbidity and MDMA use is not clearly established.

Objectives: To study, in a longitudinal case-control design, the prevalence of psychiatric disorders in a sample of MDMA users non-seeking treatment.

Subjects: Forty MDMA users non-seeking treatment and 48 matched controls.

Methods: All subjects were diagnosed (DSM-IV) in a blind manner with the validated Spanish version of a semi-structured interview specifically designed for substance abuse patients (PRISM, 1996).

Results at baseline evaluation:
1. Twenty-eight percent of cases had the diagnosis of MDMA abuse disorder and 13% had MDMA dependence disorder. Most cases showed other substance use disorder (65% cannabis, 28% alcohol, 25% cocaine). Only 2% of alcohol abuse was found in controls.
2. Thirty-two percent of cases had other psychiatric disorder non-related to substance use (affective 5%, anxiety 8%, eating 3%). Only 6% of controls had non-related to substance use psychiatric disorder (affective 2%, anxiety 2%, eating 2%).

Conclusions: MDMA users non-seeking treatment has a higher prevalence of psychiatric comorbidity than controls.

P55.06
Gambling co-morbidity in heroin addicts in MMT
M. Campana*, M. Metzger, M. Rigidieta, L. Tidone. Department of Addictive Behaviours - Asl di Bergamo; 2ECCAS-Network, Italy

Goals: to evaluate co-morbidity for gambling in a group of heroin addicted patients (according to DSM IV criteria) in Methadone maintenance treatment (MMT) for more than 3 months.

Methods: we included all the patients in MMT in a defined week and we sent to all a letter in order to clarify the goals of the research and to collect their informed consent. We used SOGS - Gambling History Test (South Oaks Clinical Team by Lesieur & Blume – 1987) submitted by a trained professional.

Results:

<table>
<thead>
<tr>
<th>MMT group</th>
<th>715</th>
</tr>
</thead>
<tbody>
<tr>
<td>MMT group &gt; 3</td>
<td>594</td>
</tr>
<tr>
<td>months</td>
<td></td>
</tr>
<tr>
<td>Tested group</td>
<td>244</td>
</tr>
<tr>
<td>M</td>
<td>204</td>
</tr>
<tr>
<td>F</td>
<td>40</td>
</tr>
</tbody>
</table>

Score

<table>
<thead>
<tr>
<th>Group</th>
<th>0–2</th>
<th>&gt;2</th>
</tr>
</thead>
<tbody>
<tr>
<td>244</td>
<td>183</td>
<td>75</td>
</tr>
<tr>
<td>19</td>
<td>27</td>
<td>42</td>
</tr>
<tr>
<td>7.8</td>
<td>17.2</td>
<td></td>
</tr>
</tbody>
</table>

Conclusions: our study shows an interesting result about pathological gambling in this specific group of patients: 25% of these has a significant score (>2) at the SOGS-test. At the present it is quite difficult to compare our results because we do not know if exist any international data about co-morbidity for gambling in addicts.

These results however confirm that it is necessary to better understand the common patterns of different addictive behaviours and to investigate the several aspects of the addictions in every patient to manage them in the best way. The mission of our Department clearly defines that every kind of addiction are to study and treat; for the next future we are defining more focused studies on this problem and we are developing a specific clinical unit to treat pathological gambling.

P55.07
Gender differences among heroin users
S.O. Mokhnatchev*. Research Institute on Addictions, Moscow, Russia

Background: wide spread of heroin abuse in Russia in recent years makes it necessary to study and understand gender differences among heroin users.